Investment Rating - The industry rating for the traditional Chinese medicine sector is maintained at "Overweight" [4] Core Views - The traditional Chinese medicine sector experienced a decline of 2.04% last week, with the overall pharmaceutical sector also showing a downward trend. The traditional Chinese medicine sector's performance was in the middle range compared to other pharmaceutical sub-sectors [1][16] - The price-to-earnings (PE) ratio for the traditional Chinese medicine sector is 26.64X, which is a decrease of 0.56X week-on-week. The price-to-book (PB) ratio is 2.24X, down 0.05X week-on-week. These ratios indicate that the sector is positioned at the 26.94% and 4.63% percentiles, respectively, since 2013 [2][18] - The three key themes for the future development of traditional Chinese medicine are inheritance, innovation, and integration. Recent government reports emphasize the importance of these themes, suggesting a shift towards high-quality development and structural differentiation in the industry [3] - The traditional Chinese medicine market is expected to benefit from policy-driven changes, particularly in the areas of essential medicine catalog adjustments and innovation. Companies with strong research and development capabilities are likely to see growth opportunities [4][8] Summary by Sections Market Performance - The traditional Chinese medicine sector reported a closing index of 6246.59 points, down 2.04% last week. The overall pharmaceutical sector index closed at 8092.32 points, down 2.78% [1][16] Valuation - The traditional Chinese medicine sector's PE (ttm) is 26.64X, with a year-high of 30.26X and a year-low of 24.72X. The PB (lf) is 2.24X, with a year-high of 2.52X and a year-low of 2.17X [2][18] Development Trends - The government has highlighted the need for a new mechanism for the review and approval of traditional Chinese medicine, integration with primary healthcare, and the cultivation of professional talent. The industry is expected to transition from scale expansion to high-quality development, with compliance and innovation as key trends [3] Investment Recommendations - The report suggests focusing on companies with evidence-based medicine, strong R&D capabilities, and quality control advantages. Key recommendations include Yiling Pharmaceutical and Zhaoke Pharmaceutical, with a focus on the recovery of consumer demand in the traditional Chinese medicine sector [4][8]

Investment Rating - The report maintains an "Overweight" rating for the in vitro diagnostics (IVD) industry [5][56]. Core Insights - The IVD industry is expected to benefit from policy support and market access optimization as part of the "14th Five-Year Plan," which emphasizes high-end medical devices and innovative technologies [4][5]. - The domestic IVD industry is in a bottoming phase, with significant progress in the localization of biochemical diagnostics, reducing reliance on foreign technologies [5][56]. - The report highlights growth opportunities in the IVD sector driven by technological integration, domestic substitution, and new screening scenarios [4][5]. Summary by Sections Industry Performance - The pharmaceutical and biological sector fell by 2.78%, while the IVD sector rose by 0.18% during the week [1]. - The IVD sector's current PE (ttm) is 39.41X, with a PB (lf) of 1.80X, showing slight increases from the previous week [3]. Market Trends - The "14th Five-Year Plan" outlines 109 major projects across six areas, focusing on public health, medical services, and innovative technologies, which will directly benefit the IVD sector [4]. - The report suggests that advancements in biomedicine materials could alleviate supply chain constraints for IVD reagents [4]. Investment Recommendations - The report recommends focusing on the growth potential in immunodiagnostics, particularly in chemiluminescence and molecular diagnostics, highlighting companies like YHLO and Shengxiang [6][56].

Investment Rating - The industry rating is maintained at "Overweight" [3][6] Core Insights - The economic theme meeting of the "Two Sessions" has been held, with a focus on the continuous reduction of risks in key areas [2][4] - The monetary policy remains accommodative, providing a favorable liquidity environment for banks, with an emphasis on promoting stable economic growth and reasonable price recovery [3][30] - The credit structure continues to optimize, focusing on key support directions such as technology, green finance, inclusive finance, and digital sectors, with loans in these areas maintaining double-digit growth [3][30] Summary by Sections Market Review - The banking index rose by 1.64% during the period from March 2 to March 8, 2026, outperforming the CSI 300 index by 2.71 percentage points [8] - The top-performing banks included Chongqing Bank (+12.46%), Chengdu Bank (+4.76%), Agricultural Bank (+4.69%), Construction Bank (+4.42%), and Transportation Bank (+3.36%) [8] Funding Market - The funding environment is relatively loose, with the central bank's net withdrawal of 15,634 million yuan [18] - The average issuance rates for 1-year interbank certificates of deposit for major banks are 1.57%, with a slight decrease compared to previous values [20] Industry and Company Dynamics - The "Two Sessions" economic theme meeting has highlighted the ongoing reduction of risks in key areas, with significant progress in resolving financing platform debt risks, with a reduction of over 70% in both the number of platforms and debt scale compared to early 2023 [4][31] - The focus on balancing risk and return in credit policies is emphasized, with banks being encouraged to avoid blind expansion and maintain a new balance among volume, price, and quality [5][31] Investment Recommendations - In the context of weak economic recovery, banks are advised to focus on balancing risk and return, which will help alleviate margin pressure and improve asset quality [6][33] - High dividend yield banks are highlighted as having significant allocation value, with recommendations for state-owned large and medium-sized banks, as well as regionally strong banks [6][33]

Investment Rating - The industry investment rating is maintained at "Overweight" [1] Core Insights - The vaccine industry is transitioning from scale expansion to innovation-driven growth, facing short-term pain due to supply-demand imbalance and homogenized competition, but the long-term positive logic remains unchanged, driven by policy, demand, and technology [8][24][27] - Recent discussions during the National People's Congress focused on building a more comprehensive "lifecycle" immunization barrier, indicating potential policy support for expanding the types of vaccines included in the national immunization program [3][4] Summary by Sections Industry Performance - The vaccine sector experienced a decline of 3.81% recently, with a cumulative drop of 14.28% since 2025 [4][10] - The overall pharmaceutical sector also saw a decline, with the medical biology index down by 2.78% [4][10] Company Developments - CanSino's MCV4 and PCV13 vaccines received GMP certification from Malaysia's NPRA, facilitating their registration in Malaysia and other PIC/S member countries [3] - Watson Bio's adsorbed tetanus vaccine has entered Phase III clinical trials, with the first phase completed [3] - Zhifei Biological's insulin injection application has been accepted by the National Medical Products Administration [3] - Kanglaisheng reported a revenue of 1.4452 million yuan for 2025, a year-on-year increase of 63.18%, but still has not achieved commercialization [3] Market Review - The vaccine sector's PE (ttm) is 65.37X, down by 1.47X from the previous period, while the PB (lf) is 1.21X, reflecting a slight decrease [6] - The vaccine industry is characterized by a high proportion of Me-too products, leading to intense competition and price declines [7][24] Investment Recommendations - The vaccine industry is under pressure, with companies encouraged to adjust their pipeline strategies focusing on technological innovation and multi-valent products [7][24] - Long-term attention should be given to companies with strong R&D capabilities and differentiated product lines, with a specific recommendation for CanSino [8][27]

Investment Rating - The industry maintains a "Buy" rating [7] Core Insights - The real estate market is showing signs of stabilization, with a focus on March transaction performance [1] - Key cities are experiencing a gradual recovery in second-hand housing transactions, with Shanghai's new policies beginning to show effects [2] - Nationally, new and second-hand housing transactions are gradually recovering post-Spring Festival, although year-on-year comparisons show declines [3] Summary by Sections Key Cities - In Beijing, the average daily transaction of second-hand homes was 494 units (down 18.4% year-on-year), while new homes saw 70 units (down 40.9%) [2] - Shenzhen reported 139 second-hand homes (down 28%) and 39 new homes (down 51%) [2] - Shanghai's second-hand homes averaged 723 units (down 18%) and new homes 213 units (down 15%), with significant increases compared to the previous lunar year [2] National Overview - In 30 major cities, new home transaction area decreased by 23.3% year-on-year, but increased by 11% compared to the previous lunar year [3] - The cumulative transaction area from January to March shows a decline of 24.4% year-on-year [3] - Second-hand homes in 14 cities saw a 24.7% year-on-year decrease, but a 10.4% increase compared to the previous lunar year [3] Investment Recommendations - The traditional peak season for real estate transactions is in March and April, with Shanghai's new policies expected to release pent-up demand [4] - The report suggests focusing on leading real estate companies with land reserves in core cities and high-end products, such as Poly Developments [4] - It also highlights the potential for valuation recovery in leading intermediary agencies as the proportion of second-hand transactions continues to rise [4]

Investment Rating - The report maintains a "Buy" rating for the medical services industry [6][10] Core Insights - The medical and biological sector experienced a decline of 2.78%, ranking 17th among 31 primary industries [2] - The government has elevated the strategic importance of the biopharmaceutical industry, designating it as a "new pillar industry" [5][6] - The focus for 2026 has shifted towards "high-quality" development in innovative pharmaceuticals and medical devices [6] Summary by Sections Industry Performance - The medical services sector's PE (ttm) is 32.48X, with a recent decline of 1.63X, while the PB (lf) is 3.29X, down by 0.16X [4] - The medical services sector index closed at 6863.51 points, down 4.71% for the week, but up 33.71% year-to-date [25] Government Initiatives - The government aims to enhance the medical service system, optimize medical insurance and procurement, and expand long-term care insurance coverage to 300 million people [5] - Key tasks for 2026 include improving emergency services, optimizing medical layouts, and promoting collaboration between traditional and Western medicine [6] Company Performance - Notable performers in the medical services sector include International Medicine (+4.2%), Nuotai Biological (+3.9%), and Heyuan Biological (+3.1%) [3] - Underperformers include Haoyuan Pharmaceutical (-12.3%) and Nossger (-10.3%) [3] Investment Recommendations - Focus on high-growth areas such as ADC CDMO and peptide CDMO in the pharmaceutical outsourcing sector, with companies like WuXi AppTec and Haoyuan Pharmaceutical highlighted [10] - Consider companies in the third-party testing laboratories and consumer healthcare sectors, such as Aier Eye Hospital and Dean Diagnostics, which are expected to see a recovery in profitability [10]

Investment Rating - The industry investment rating is maintained as "Buy" [2] Core Views - The food and beverage industry has experienced a decline of 2.48% from March 2 to March 6, 2026, underperforming the CSI 300 index by 1.41 percentage points [4][9] - The current valuation of the food and beverage industry is at a historical low, with a PE ratio of 20X, ranking 24th among Shenwan's primary industries [5][15] - The decline in raw milk prices is slowing, with the average price in major production areas at 3.03 RMB/kg, down 1.90% year-on-year [5][28] - The investment suggestion highlights three main lines: focusing on industry leaders with stable demand, companies actively developing new products and channels, and segments with high growth potential and reasonable valuations [7][40] Summary by Sections Industry Performance - From March 2 to March 6, 2026, the food and beverage industry fell by 2.48%, ranking 14th out of 31 sectors, with meat products, beer, and dairy showing slight increases [4][9] Valuation Insights - As of March 6, 2026, the food and beverage industry's PE ratio is 20X, with other liquor at 50X, snacks at 34X, and health products at 33X, while white liquor, beer, and dairy are lower at 18X, 23X, and 23X respectively [5][15] Price Tracking - Raw milk prices are stabilizing, with the average price at 3.03 RMB/kg, and yogurt and milk prices showing slight changes [5][28] - Pork prices are declining in the off-season, with average prices for piglets at 27.67 RMB/kg and live pigs at 12.45 RMB/kg [6][30] Investment Recommendations - The report suggests focusing on three main lines for investment: industry leaders with strong demand, companies innovating in products and channels, and segments with solid growth and low valuations [7][40]

Core Insights - The A-share indices experienced a downward trend due to escalating conflicts in the Middle East, particularly the blockade of the Strait of Hormuz by Iran, which led to a significant rise in international oil prices and increased global inflation expectations [2][12] Industry Performance - Among the 31 first-level industries, the top gainers were Oil and Petrochemicals and Coal, with increases of 8.06% and 3.79% respectively, while the largest declines were seen in Media and Non-ferrous Metals, which fell by 6.97% and 5.47% respectively [3][18] - In the 124 second-level industries, the best performers were Oil Service Engineering and Electric Grid Equipment, with weekly gains of 12.73% and 6.66%. Year-to-date, Oil Service Engineering and Small Metals led with increases of 60.08% and 41.71% respectively. The largest weekly declines were in Energy Metals and Digital Media, down 9.22% and 8.24% respectively, with year-to-date declines in Aviation Airports and State-owned Large Banks II of 12.79% and 8.69% respectively [3][21] - In the 259 third-level industries, the top gainers were Coal Chemical and Oil and Gas Refining Engineering, with weekly increases of 15.17% and 14.58%. Year-to-date, Oil and Gas Refining Engineering and Communication Cables and Accessories led with increases of 75.77% and 54.40% respectively. The largest weekly declines were in Photovoltaic Processing Equipment and Communication Value-added Services, down 12.18% and 10.42% respectively, with year-to-date declines in Aviation Transportation and Brand Consumer Electronics of 14.29% and 9.99% respectively [4][22] Investment Recommendations - The report suggests a long-term view for 2026, indicating it is the beginning year of the "14th Five-Year Plan," with the central bank implementing proactive fiscal policies and moderately loose monetary policies to support stable economic growth and maintain a "slow bull" market for A-shares [5][24] - Short-term focus should be on sectors benefiting from the "14th Five-Year Plan" related to new productivity (technology, environmental protection), structural opportunities in traditional sectors related to "anti-involution," defensive dividend sectors related to long-term capital inflows, and sectors benefiting from the Middle East conflict [5][24]

Investment Rating - The report maintains a "Buy" rating for the machinery industry [3] Core Views - The machinery industry underperformed the market this week, with the Shanghai Composite Index down 1.1% and the machinery sector down 2.8%. The best-performing sub-sector was laser equipment, which increased by 7.8% [3][10] - In the first two months of 2026, excavator sales in China increased by 13.1% year-on-year, with domestic sales down 9.2% and exports up 38.8%. Loader sales also showed growth, with a total increase of 27.9% year-on-year [4] - The demand for gas turbines is expected to surge due to increased investment in data centers by major tech companies, leading to a significant rise in electricity demand [5] - The ongoing conflict between the U.S. and Iran has caused a spike in global oil and gas prices, which may drive demand for oil service equipment and shipping [6] Summary by Sections Market Review - The machinery industry has seen a cumulative increase of 10.8% this year, with laser equipment leading the gains at 47.2% [3][11] - The report highlights the seasonal factors affecting domestic sales of excavators and loaders, attributing the decline in February to the Spring Festival and previous high sales [4] Engineering Machinery - Excavator sales in February showed a year-on-year decline of 10.6%, with domestic sales down 42.0% but exports up 37.2%. The report anticipates a recovery in domestic sales driven by ongoing demand for equipment updates and electric machinery [4] Gas Turbines - Major tech companies have committed to self-supplying electricity for AI data centers, leading to increased demand for gas turbines, which are favored for their quick deployment and low operational costs [5] Oil Service Equipment - The report notes that the U.S.-Iran conflict has led to a significant increase in oil prices, which may boost capital expenditures in the oil and gas sector [6] Investment Recommendations - The report suggests focusing on the engineering machinery sector, where demand is expected to rebound due to equipment updates and high commodity prices driving overseas demand. Key companies to watch include SANY Heavy Industry, XCMG, and Zoomlion [7][29] - The gas turbine sector is highlighted for its potential growth due to the surge in electricity demand from data centers. Companies like Haomai Technology and leading turbine manufacturers are recommended for investment [7][30] - The oil service equipment sector is also recommended, with a focus on domestic leaders in oil service and shipping due to rising prices [8][30]

Investment Rating - The industry investment rating is maintained at "Overweight" [2][41] Core Insights - The tungsten industry continues to show strong market performance, with a cumulative increase of 35.91% in February, significantly outperforming the benchmark (CSI 300) by 35.82 percentage points [5] - The valuation of the industry (TTM P/E ratio) has risen from 55.45x at the beginning of the month to 75.76x, currently at 97.52% of its historical percentile [5] - Domestic tungsten product prices have surged due to tight resource supply, with significant increases in both black and white tungsten concentrate prices [6][8] - The international tungsten prices have also risen, reflecting the upward trend in domestic prices [8] Monthly Performance Summary - In February, the domestic tungsten concentrate price for 65% black tungsten increased by 32.89% month-on-month to 684,500 CNY/ton, and by 375.35% year-on-year [8] - The price for 65% white tungsten rose by 32.92% month-on-month to 682,000 CNY/ton, with a year-on-year increase of 379.06% [8] - The ammonium paratungstate (88.5%) price increased by 32.63% month-on-month to 1,006,000 CNY/ton, with a year-on-year increase of 374.87% [8] - Tungsten powder prices also saw significant month-on-month increases, with prices for tungsten powder (≥99.7%, 2-10um) rising by 37.32% to 1,717.5 CNY/kg, and a year-on-year increase of 440.99% [8] Supply and Demand Dynamics - The tungsten supply chain is experiencing a seasonal decline in production, exacerbating supply tightness, with domestic tungsten concentrate production dropping by 39.46% month-on-month in February [9] - The operating rate for tungsten concentrate production fell to 35.31%, below the previous year's levels during the Spring Festival [9] - Inventory levels across the tungsten supply chain are at historical lows, with significant reductions in stock for tungsten concentrate, ammonium paratungstate, and tungsten powder [11] Profit Distribution and Market Outlook - The profit margins for tungsten concentrate are expanding due to resource scarcity and price increases, with simulated gross profit reaching 539,400 CNY/ton, a month-on-month growth of 50.71% [11] - The midstream sector is also seeing profit expansion, while the downstream sector faces pressure due to cost transmission issues [11] - Long-term, the tightening of tungsten supply due to various factors, including declining ore grades and stricter mining controls, is expected to support higher tungsten prices [11][38] - The report suggests that the first batch of tungsten mining control indicators for 2026 is expected to tighten, reinforcing the supply constraint logic [38]